Inicio › Dermatitis atópica (eccema) › Texas
Ensayos clínicos de Dermatitis atópica (eccema) en Texas
18 estudios sobre Dermatitis atópica (eccema) buscan participantes en Texas.
Ciudades en Texas
Texto oficial del estudio (inglés)
This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Reveal Research Institute - Dallas- Site Number : 8400012, Dallas
- Austin Institute for Clinical Research, Inc- Site Number : 8400030, Pflugerville
- Complete Dermatology - Sugar Land- Site Number : 8400001, Sugar Land
ReclutandoEstudio observacional
Edades de 12 en adelante · Todos los sexos · Actualizado el 29 sept 2026 · NCT07290803Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 102, College Station
- Clinical Site 104, San Antonio
ReclutandoFase 1Se aceptan voluntarios sanos
Edades de 18 a 65 · Todos los sexos · Actualizado el 29 sept 2026 · NCT07453602Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Arlington
- Novartis Investigative Site, Cypress
- Novartis Investigative Site, Dallas
- y 2 más
ReclutandoFase 2
Edades de 18 a 100 · Todos los sexos · Actualizado el 28 sept 2026 · NCT06947993A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Texas Dermatology and Laser Specialists, San Antonio
ReclutandoFase 3
Edades de 2 a 11 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06807281First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Texas Dermatology and Laser Specialists, San Antonio
ReclutandoFase 1Se aceptan voluntarios sanos
Edades de 18 a 65 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07527923Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Arlington
- Enveda Investigative Site, Houston
- Enveda Investigative Site, San Antonio
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT07298395A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Dallas
- Investigational Site, Frisco
- Investigational Site, San Antonio
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Harrison Dermatology, Missouri City
ReclutandoEstudio observacional
Edades de 12 a 89 · Todos los sexos · Actualizado el 15 sept 2026 · NCT07645820A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
- ALS Global, Irving
ReclutandoFase 2/3
Edades de 18 a 80 · Todos los sexos · Actualizado el 4 sept 2026 · NCT07355075A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Progressive Clinical Research, PA, San Antonio
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 28 ago 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
ReclutandoFase 2
Edades de 18 a 74 · Todos los sexos · Actualizado el 12 ago 2026 · NCT07037901A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Dallas
- Enveda Investigative Site, San Antonio
- Enveda Investigative Site, Sugar Land
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Arlington Research Center, Inc /ID# 266330, Arlington
- 3A Research - East location /ID# 267622, El Paso
- Prime Clinical Research - Mansfield - East Broad Street /ID# 268042, Mansfield
- y 2 más
ReclutandoFase 3
Edades de 2 a 11 · Todos los sexos · Actualizado el 6 ago 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Arlington Research Center, Inc /ID# 263665, Arlington
- Studies in Dermatology LLC /ID# 263335, Cypress
- Dermatology Treatment and Research Center /ID# 265812, Dallas
- y 6 más
ReclutandoFase 3
Edades de 18 a 63 · Todos los sexos · Actualizado el 6 jul 2026 · NCT06389136Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
- UT Health Science Houston, Bellaire
- Center for Clinical Studies, Webster
ReclutandoFase 2
Edades de 18 a 65 · Todos los sexos · Actualizado el 15 jun 2026 · NCT06397911A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dermatology Treatment and Research Center, Dallas
- North Texas Center for Clinical Research, Frisco
- DCT-Stone Oak, LLC dba Discovery Clinical Trials, San Antonio
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 4 may 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7082, Cedar Park
- Galderma Investigational Site 8238, Dallas
- Galderma Investigational Site 7062, Edinburg
- y 3 más
ReclutandoEstudio observacional
Edades de 12 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT06988605Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
- Clinical Investigations of Texas, Dallas
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 dic 2025 · NCT06982352De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.